Table of Contents Table of Contents
Previous Page  149 / 916 Next Page
Show Menu
Previous Page 149 / 916 Next Page
Page Background

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S106–S169


tion and the extent to which psychiatric co-morbidity is taken into



To determine, whether MDD should be considered an

episodic or chronic disorder.


To examine the 6 year course of MDD, incorporating

data of multiple time points and taking common psychiatric co-

morbidities into account.


Data were from903 patients with current MDD at base-

line in the Netherlands study of depression and anxiety, with

subsequent data from 2 year, 4 year and 6 year follow-up. Four

course trajectories were created taking all information during

follow-up into account classifying patients as (1) recovered, (2)

recurrent without chronic episodes, (3) recurrent with chronic

episodes or (4) consistently chronic. A chronic episode was defined

as having symptoms consistently over 2 years.


The recovery rate of MDDwas 58% at 2 year follow-up but

looking at 6 year follow-up and taking into account co-morbid dys-

thymia, (hypo) mania and anxiety disorders reduced this recovery

rate to 17%. Moreover, more than half of the patients experienced

chronic episodes.


Longitudinal data of this psychiatric cohort study

showed that full recovery is the exception rather than the rule.

MDD follows a chronic course and, moreover, persons are prone

to switch to other psychiatric disorders.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Mirtazapine and trazodone efficacy on

major depressive disorder (MDD) is

moderated by patients’ age and sex:

A randomized, controlled trial

M. Vilibi´c

1 ,

, ˇ Z. ˇ

Surina Osmak

2 , M.


3 , B. K


4 ,

V. Juki´c



University Psychiatric Hospital Vrapˇce, Department of Biological

Psychiatry and Psychogeriatrics, Zagreb, Croatia


Ministry of Defence of the Republic of Croatia, Department of

Health, Zagreb, Croatia


Medical School, University of Rijeka, Department of Social Medicine

and Epidemiology, Rijeka, Croatia


Andrija ˇStampar Teaching Institute of Public Health, Service for

Epidemiology, Zagreb, Croatia


University Psychiatric Hospital Vrapˇce, Department of Forensic

Psychiatry, Zagreb, Croatia

Corresponding author.


NaSSA antidepressant mirtazapine and SARI tra-

zodone has proven efficacy on MDD.


To compare differences in mirtazapine and trazodone effi-

cacy on MDD in different age and sex groups.


A consecutive sample of 60 MDD outpatients were ran-

domized to mirtazapine 30mg/day or trazodone 150mg/day for a

3months stable dosing period at the department of biological psy-

chiatry and psychogeriatrics of the university psychiatric hospital

Vrapˇce, Croatia. Outcome was relative lowering of HAMD-17 scale

result. The study was single blind: rater was blinded, while patients

informed regarding prescribed medication.


Overall efficacy of mirtazapine and trazodone was com-

parable (84% lowering of HAMD–17 in both cases; difference


= 0.754). After adjustment for MDD baseline severity (CGI–S),

education, marital and working status, interaction of age and sex

significantly moderated two drugs’ efficacies. In patients older

than 47 years, in male patients trazodone was significantly more

effective, and in female patients significantly less effective than

mirtazapine. This effect was increasing by aging.


Mirtazapine and trazodone efficacy on MDD is mod-

erated by patients’ age and sex.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Early prediction of non-response to

anti-depressive treatment with an

easy-to-use electrophysiological index


S. Yariv

1 ,

, G. Shahaf


, B. Bloch


, A. Reshef


, Y. Bloch



Emek Medical Center, Psychiatry, Afula, Israel


BrainMARC, Chief Scientist, Yoqneam, Israel


Shalvata Mental Health Center, Child and Adolescent Outpatient

clinic, Hod Hasharon, Israel

Corresponding author.


The evaluation of response to pharmacological

treatment in MDD requires 6–8 weeks. Therefore, the ability

to predict response, and especially lack of response to treat-

ment, as early as possible after treatment onset or change, is of

major significance. Many studies demonstrated significant results

regarding the ability to use EEG and ERP markers. However,

these markers are derived from long EEG/ERP samples, often from

multiple channels, which render them impractical for frequent



We developed a new electrophysiological attention-

related marker from a single channel (2 electrodes) and 1minute

samples. This work presents an initial evaluation of the ability to

harness this marker, for early differentiation between responders

and non-responders to anti-depressive treatment, in 26 patients

with various levels of depression and heterogeneous treatment

interventions and 10 healthy controls. Subjects who initiated

treatment for depression were followed clinically through their

Hamilton depression scores as well as their EEG activity twice

a week for a period of 8 weeks. Any acceptable anti-depressive

treatment been included. The improvement in Hamilton scores

at the end of 8 weeks used to discriminate responders and non-



Within two weeks, we could differentiate between non-

responders and responders to anti-depressive treatment, with

absolute discrimination between subjects with moderate to severe

depression, andwith 0.71 sensitivity and 0.96 specificity within the

whole depressed subjects.


This is a proof of concept for an easy to use, cheap and

quick marker for the lack of respond to anti-depressive treatment

within two weeks of anti-depressive treatment.

Disclosure of interest

Relevant: BrainMARC ltd funded the study.

Non relevant: Lundbeck Israel- honorarium.

Unipharm ltd honorarium.


The dopaminergic polymorphisms in

psychomotor retardation of

depression: A pathway-based imaging

genetics association study

Y. Yin

, Y. Yuan

Affiliated ZhongDa Hospital and Institute of Neuropsychiatry of

Southeast Univer, Department of Psychosomatics and Psychiatry,

ZhongDa Hospital School of Medicine Southeast University, Nanjing,


Corresponding author.


Several lines of evidence implicate dopamine is

involved in the psychomotor retardation (PMR) in major depres-

sive disorder (MDD). Besides, abnormal cerebral blood flow (CBF) of

PMR was also found in the cortico-basal ganglia-thalamo-cortical